Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

IBIS-II investigators

Research output: Contribution to journalArticlepeer-review

378 Citations (Scopus)
286 Downloads (Pure)

Abstract

Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease.
Original languageEnglish
Pages (from-to)1041-8
Number of pages8
JournalLancet
Volume383
DOIs
Publication statusPublished - 22 Mar 2014

Keywords

  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Carcinoma, Intraductal, Noninfiltrating
  • Carcinoma, Lobular
  • Double-Blind Method
  • Female
  • Humans
  • Longitudinal Studies
  • Middle Aged
  • Nitriles
  • Postmenopause
  • Proportional Hazards Models
  • Risk Factors
  • Treatment Outcome
  • Triazoles

Fingerprint

Dive into the research topics of 'Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial'. Together they form a unique fingerprint.

Cite this